Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Determination of meglumine in pharmaceutical formulations using high performance liquid chromatography.

Jasprica I, Mrsić N, Dragić T, Cetina-Cizmek B.

Pharmazie. 2011 Dec;66(12):916-9.

PMID:
22312693
2.

Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice.

Naarding MA, Falkowska E, Xiao H, Dragic T.

Vaccine. 2011 Apr 5;29(16):2910-7. doi: 10.1016/j.vaccine.2011.02.009. Epub 2011 Feb 21.

PMID:
21338680
3.

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.

Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF.

Gastroenterology. 2010 Sep;139(3):953-64, 964.e1-4. doi: 10.1053/j.gastro.2010.05.073. Epub 2010 Jun 2.

4.

Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts.

Cukierman L, Meertens L, Bertaux C, Kajumo F, Dragic T.

J Virol. 2009 Jun;83(11):5477-84. doi: 10.1128/JVI.02262-08. Epub 2009 Mar 18.

5.

Mouse mammary tumor virus uses mouse but not human transferrin receptor 1 to reach a low pH compartment and infect cells.

Wang E, Obeng-Adjei N, Ying Q, Meertens L, Dragic T, Davey RA, Ross SR.

Virology. 2008 Nov 25;381(2):230-40. doi: 10.1016/j.virol.2008.08.013. Epub 2008 Oct 1.

6.

The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus.

Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, Dragic T.

J Virol. 2008 Apr;82(7):3555-60. doi: 10.1128/JVI.01977-07. Epub 2008 Jan 30.

7.

Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.

Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T.

J Virol. 2007 Aug;81(15):8072-9. Epub 2007 May 16.

8.

Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions.

Bertaux C, Daelemans D, Meertens L, Cormier EG, Reinus JF, Peumans WJ, Van Damme EJ, Igarashi Y, Oki T, Schols D, Dragic T, Balzarini J.

Virology. 2007 Sep 15;366(1):40-50. Epub 2007 May 11.

9.
10.

L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles.

Falkowska E, Durso RJ, Gardner JP, Cormier EG, Arrigale RA, Ogawa RN, Donovan GP, Maddon PJ, Olson WC, Dragic T.

J Gen Virol. 2006 Sep;87(Pt 9):2571-6.

PMID:
16894195
11.
12.
13.

Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM, Smith SO, Dragic T, Moore JP, Sakmar TP.

Virology. 2006 May 25;349(1):41-54. Epub 2006 Feb 21.

15.

L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.

Cormier EG, Durso RJ, Tsamis F, Boussemart L, Manix C, Olson WC, Gardner JP, Dragic T.

Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14067-72. Epub 2004 Sep 15.

16.

CD81 is an entry coreceptor for hepatitis C virus.

Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T.

Proc Natl Acad Sci U S A. 2004 May 11;101(19):7270-4. Epub 2004 May 3.

17.
18.

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T.

J Virol. 2003 May;77(9):5201-8.

19.

L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus.

Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4498-503. Epub 2003 Apr 3.

21.

CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates.

Thompson DA, Cormier EG, Dragic T.

J Virol. 2002 Mar;76(6):3059-64.

22.

An overview of the determinants of CCR5 and CXCR4 co-receptor function.

Dragic T.

J Gen Virol. 2001 Aug;82(Pt 8):1807-14. Review. No abstract available.

PMID:
11457985
23.
24.

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.

Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC.

J Infect Dis. 2001 Apr 1;183(7):1121-5. Epub 2001 Mar 8.

PMID:
11237840
26.

Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Cormier EG, Persuh M, Thompson DA, Lin SW, Sakmar TP, Olson WC, Dragic T.

Proc Natl Acad Sci U S A. 2000 May 23;97(11):5762-7.

27.
28.

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44.

29.

HIV. See a pocket, block it.

Moore JP, Dragic T.

Nature. 1999 Oct 21;401(6755):759. No abstract available.

PMID:
10548097
30.

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.

J Virol. 1999 May;73(5):4145-55.

32.

Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.

Zhang YJ, Dragic T, Cao Y, Kostrikis L, Kwon DS, Littman DR, KewalRamani VN, Moore JP.

J Virol. 1998 Nov;72(11):9337-44.

34.

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ.

J Virol. 1998 Jan;72(1):279-85.

35.

Co-receptors for HIV-1 entry.

Moore JP, Trkola A, Dragic T.

Curr Opin Immunol. 1997 Aug;9(4):551-62. Review.

PMID:
9287172
36.

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP.

Nature. 1996 Nov 14;384(6605):184-7.

PMID:
8906796
37.

The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons.

Paxton WA, Dragic T, Koup RA, Moore JP.

AIDS Res Hum Retroviruses. 1996 Sep 1;12(13):1203-7. Review. No abstract available.

PMID:
8870841
38.

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA.

Nature. 1996 Jun 20;381(6584):667-73.

PMID:
8649512
40.

Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26.

Lazaro I, Naniche D, Signoret N, Bernard AM, Marguet D, Klatzmann D, Dragic T, Alizon M, Sattentau Q.

J Virol. 1994 Oct;68(10):6535-46.

41.

CD26 antigen and HIV fusion?

Alizon M, Dragic T.

Science. 1994 May 20;264(5162):1161-2; author reply 1162-5. No abstract available.

PMID:
7909962
43.
44.

[Demonstration of an engagement process towards cell death by apoptosis in lymphocytes of HIV infected patients].

Gougeon ML, Olivier R, Garcia S, Guetard D, Dragic T, Dauguet C, Montagnier L.

C R Acad Sci III. 1991;312(11):529-37. French.

PMID:
1648991

Supplemental Content

Loading ...
Support Center